Solid Biosciences (SLDB) Total Liabilities (2017 - 2026)

Solid Biosciences has reported Total Liabilities for 10 years, with the latest figure at $48.8 million in Q1 2026.

• Quarterly Total Liabilities fell 1.38% year-over-year to $48.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $48.8 million (down 1.38% YoY) and the FY2025 annual result came in at $52.5 million, up 2.17% from the prior year.
• Total Liabilities eased to $48.8 million in Q1 2026 per SLDB's latest filing, from $52.5 million in the prior quarter.
• Over five years, Total Liabilities peaked at $56.0 million in Q3 2025 and troughed at $22.0 million in Q1 2022.
• A 5-year average of $44.3 million and a median of $45.8 million in 2023 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2022 and 2023: Total Liabilities sank 31.7% in 2022, then jumped 107.76% in 2023.
• Over 5 years, Total Liabilities stood at $48.6 million in 2022, then fell by 20.85% to $38.5 million in 2023, then surged by 33.69% to $51.4 million in 2024, then grew by 2.17% to $52.5 million in 2025, then fell by 7.17% to $48.8 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $48.8 million, $52.5 million, and $56.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.